Simplified Consent Arrangements for Adults Lacking Capacity (UK Clinical Trials)

Simplified consent arrangements for adults lacking capacity is UK research-governance shorthand for how clinical trials of investigational medicinal products (CTIMPs) handle informed consent when a participant cannot give it themselves — whether because of an existing condition (e.g. advanced dementia) or a sudden, incapacitating event (e.g. stroke, cardiac arrest, major trauma).

Why a separate regime exists

England and Wales run two distinct legal frameworks for research involving adults who lack mental capacity. Non-CTIMP intrusive research follows the Mental Capacity Act 2005, using a consultee model. CTIMPs are carved out of that Act specifically: Section 30 of the MCA excludes clinical trials from its research provisions because a dedicated regime already existed, set out in Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031), as amended. The Health Research Authority (HRA) is explicit that these are two separate regulatory regimes and that they should not be conflated when preparing consent documentation.

The legal representative pathway

Instead of consultee advice, Schedule 1, Part 5 of the 2004 Regulations requires consent from a legal representative acting on the incapacitated adult’s behalf, in a defined order of preference:

• Personal legal representative — a person not connected with the conduct of the trial who is suitable to act by virtue of their relationship with the adult (typically next of kin or someone close to them), and who is both available and willing to do so.
• Professional legal representative — used only where no personal legal representative is available; typically the doctor primarily responsible for the adult’s medical treatment (provided they are independent of the trial) or a person nominated by the relevant health service body.

This is the “simplified” element in the everyday, non-technical sense researchers and RECs use the phrase: consent is obtained from someone standing in for the participant, following a clear hierarchy, rather than through the adult’s own informed consent process.

The narrower urgent-situation exception

A second, tighter simplification applies specifically to time-critical research, most relevant to emergency medicine and critical care trials. Where a trial protocol has been specifically approved by a recognised Research Ethics Committee to cover enrolment in urgent situations, an incapacitated adult may be entered into the trial with no prior consultation of any legal representative at all, provided:

• urgent action is needed to administer the investigational medicinal product within the trial’s required timeframe, and
• it is not reasonably practicable to consult a personal or professional legal representative before that action must be taken.

Where this exception is used, the trial team must still seek consent (for continued participation) from a legal representative, or from the participant directly if and when capacity is regained, as soon as reasonably possible afterwards. This provision — introduced by a 2006 amendment to the 2004 Regulations — is what makes genuinely urgent, unconscious-patient emergency research legally possible in the UK at all; without it, time-critical trials in stroke, resuscitation, and major trauma would be largely unworkable, since there would be no route to enrolment within the clinically relevant window.

How this differs from the US approach

Researchers moving between jurisdictions sometimes assume the UK urgent-situation exception is equivalent to the US FDA’s Exception from Informed Consent (EFIC) provisions under 21 CFR 50.24. The underlying problem — enrolling incapacitated patients in emergency research within a narrow treatment window — is similar, but the mechanisms differ in structure and specific conditions (see the comparison in CASRAI’s EFIC entry). Do not assume UK REC approval of an urgent-situation protocol satisfies US EFIC requirements, or vice versa, for a multinational trial.

Practical implications for research teams

Sponsors and investigators running CTIMPs that may enrol adults lacking capacity need to: build the personal/professional legal representative hierarchy into site procedures and participant information materials; decide at protocol-design stage whether the trial requires urgent-situation provisions, since these must be specifically approved by the REC in advance and cannot be improvised after the fact; and keep this pathway clearly separate from Mental Capacity Act consultee processes used in non-CTIMP studies at the same site, since mixing the two frameworks in a single SOP is a common source of governance error.